From: Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease
Qualitative variables | n | Pvalue | |
---|---|---|---|
Female | 102 | .22 | |
∆F508 homozygous mutation | 79 | .02 | |
Exocrine pancreatic insufficiency | 102 | .55 | |
Pseudomonas aeruginosa | 99 | .36 | |
Quantitative variables | n | Correlation (r) | |
Age, years | 102 | −0.11 | .29 |
BMI, kg/m2* | 102 | 0.26 | .009 |
Leukocytosis, 109/mm3 | 70 | −0.42 | .0003 |
CRP, mg/L | 64 | −0.34 | .006 |
Serum albumin, g/L | 43 | 0.34 | .02 |
FEV1 a* | 102 | 0.71 | < .0001 |
FVCa* | 102 | 0.69 | < .0001 |
RVa | 79 | −0.58 | < .0001 |
DLCOa | 68 | 0.56 | < .0001 |
PaO2, mm Hg | 98 | 0.43 | < .0001 |
PaCO2, mm Hg | 98 | 0.11 | .29 |
Cardiopulmonary exercise parameters | n | Correlation (r) | |
VE peak, L | 102 | 0.64 | < .0001 |
VE/VCO2 peak* | 98 | −0.35 | < .0001 |
BR, %* | 102 | 0.37 | .0001 |
VD/VT peak* | 96 | −0.64 | < .0001 |
PaCO2 peak, mm Hg* | 97 | −0.45 | < .0001 |
P(A-a)O2 peak, mm Hg* | 97 | −0.54 | < .0001 |
Lactatemia peak, mmol/L* | 86 | 0.59 | < .0001 |
HR peaka | 102 | 0.40 | < .0001 |